{
    "nctId": "NCT06632405",
    "briefTitle": "A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC",
    "officialTitle": "Camrelizumab Plus Nab-paclitaxel and Anti-histamine Drug Levocetirizine in Metastatic or Recurrent Triple-negative Breast Cancer: a Randomized, Double-arm, Phase 2 Randomized Controlled Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Overall response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Sign the written informed consent;\n2. Aged \u2265 18 and \u2264 70 years old;\n3. Confirmed recurrent and metastatic triple negative breast cancer by imaging and pathology (ER negative (IHC ER positive percentage \\< 1%), PR negative (IHC PR positive percentage \\< 1%), HER2 negative (IHC -/+or IHC++but FISH/CISH -)), at least one measurable focus meeting the RECIST v1.1 standard;\n4. Untreated local recurrence of unresectable TNBC or untreated distant metastasis of TNBC\n5. Must be able to swallow tablets;\n6. Clarify the positive status of PD-L1 expression and CPS score \u2265 1\n7. ECOG score: 0 to 1;\n8. Expected survival period \u2265 12 weeks;\n9. The results of patient's blood tests are as follows (excluding the use of any blood components and cell growth factors during screening):\n\n   * Absolute neutrophil count \u2265 1.5 \u00d7 109/L;\n   * Platelets \u2265 100 \u00d7 109/L;\n   * Hemoglobin \u2265 9g/dL;\n   * Serum albumin \u2265 3g/dL;\n   * Thyroid stimulating hormone (TSH) \u2264 ULN (if abnormal, T3 and T4 levels should be examined simultaneously. If T3 and T4 levels are normal, they can be included in the group);\n   * Bilirubin \u2264 1.0 times ULN (Gilbert's syndrome or liver metastasis subject total bilirubin \u2264 1.5 times ULN);\n   * ALT and AST \u2264 1.5 times ULN (liver metastasis subjects \u2264 3 times ULN);\n   * AKP \u2264 2.5 times ULN;\n   * Renal function within 7 days before the first administration: serum creatinine \u2264 1.5 times ULN or creatinine clearance rate \u2265 60mL/min (using the standard Cockcroft Gault formula, see Appendix 3);\n10. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.\n11. Left ventricular ejection fraction \u2265 50%\n\nExclusion Criteria:\n\n1. Received other interventional clinical trials within 28 days before the first dose;\n2. Failure to recover from adverse reactions of previous treatment\n3. Neurological disorders of grade \u2265 2\n4. Untreated active brain metastases or meningeal metastases\n5. Previously received nab-paclitaxel neoadjuvant therapy or adjuvant therapy and experienced local recurrence or distant metastasis within 12 months;\n6. Has experienced severe allergic reactions to other monoclonal antibodies;\n7. Received other anti-tumor treatments within 28 days before the first administration;\n8. Suffering from hypertension and unable to achieve good control with antihypertensive medication (systolic blood pressure \u2265 140 mmHg or diastolic blood pressure \u2265 90 mmHg);\n9. Received antibody or T cell co stimulatory therapy such as PD-1, PD-L1, PD-L2, CTLA-4, Tim3, LAG3, etc;\n10. Special genetic diseases (including rare galactose intolerance, primary lactase deficiency, or glucose galactose malabsorption);\n11. Active autoimmune disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or complete remission of childhood asthma without any intervention in adulthood may be included; subjects with asthma requiring medical intervention with bronchodilators may not be included);\n12. Heart diseases, such as:\n\n    * NYHA grade 2 or above heart failure\n    * Unstable angina pectoris\n    * Have experienced a myocardial infarction within the past year\n    * Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention\uff1b\n13. Urine protein level is \u2265++, or the 24-hour urine protein level is \u2265 1.0 g;\n14. Known genetic or acquired bleeding and thrombophilia tendencies (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, splenomegaly, etc.);\n15. Have a history of tuberculosis;\n16. Active period of HBV or HCV, and other active infectious diseases;\n17. Had or is currently experiencing qualitative pneumonia or requires steroid treatment for pneumonia;\n18. Congenital or acquired immune dysfunction (such as HIV infected individuals);\n19. Received or about to receive a live vaccine within 4 weeks prior to the study or possibly during the study period;\n20. Allergic or contraindicated to the experimental drug.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}